Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.
about
Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restrictionT-cell receptor gene therapy--ready to go viral?How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferThe peptide-specific alloreactive human T cell repertoire varies largely between individuals and is not extended in HLA-A*0205--anti-HLA-A*0201 pairings.A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell functionDirect recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function.CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorHigh-throughput identification of antigen-specific TCRs by TCR gene capture.Prospects for immunotherapy of malignant disease.Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Identities of P2 and P3 Residues of H-2Kb-Bound Peptides Determine Mouse Ly49C Recognition.Improving TCR Gene Therapy for Treatment of Haematological Malignancies.Exploiting alloreactivity for tumour immunotherapy.Exploiting T cell receptor genes for cancer immunotherapy.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Antigen-specific cellular immunotherapy of leukemia.Exploiting beneficial alloreactive T cells.Can immunotherapy specifically target acute myeloid leukemic stem cells?MHC restriction and allogeneic immune responses.Enhanced T cell receptor gene therapy for cancer.Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.Challenges in T cell receptor gene therapy.Cellular immunotherapy strategies for Ewing sarcoma.Tools to define the melanoma-associated immunopeptidome.How an alloreactive T-cell receptor achieves peptide and MHC specificity.Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules.The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules.Turn to TCRs when CARs fail.No hiding place for BOB inside myeloma.Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion MedicineMyeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
P2860
Q27676136-E6688D8C-B8AD-497B-90F9-76320ED442A2Q28081611-6CB329EE-4E87-4F06-91B7-4B9C37188CF9Q28727481-4E0874D7-DB67-4A70-A398-19BD8C3C8A03Q30684229-BC63CBA3-71EC-4130-9AE7-EFF2593666B0Q33281005-BEEA9174-2DEF-4DC9-9FF7-5C6C73257109Q33943814-4B134D6B-3CA6-4AD9-863F-B73839233F3BQ34981606-FA47476D-C6BC-4094-A053-F9DDDEAF2FDFQ35016476-FA96E2EA-C086-4CB5-A657-F5ED8A4D9649Q35041705-E1C9D1CE-AA1F-4C7E-89F5-F30FA85FBD03Q35196739-9E186A1B-4B1E-42F8-8688-929999A8BDCDQ35683920-446E5ED6-5906-426F-A70D-06990E515825Q35738738-32BF5744-E4AE-48A0-AB11-559A0BC3EC5CQ35813110-38A5D087-EE09-4BA5-953F-48F195A602FAQ36011784-5540DF82-064E-443E-888A-70904E26CD37Q36239656-2CD17846-251E-4DCA-A0B6-CB0EA1277B4EQ36240201-7F1ECE2D-7F3F-45C7-B7F3-8F22A6E7BCACQ36498418-67129CDD-1D69-43EB-80AF-59479349F78EQ36694901-5C86F7B2-3068-4B4E-B12F-98261A519FB3Q37464963-A361DE24-877A-46CF-B9D6-C6F2842D5079Q37702226-3FD33723-DE4B-4811-9FF9-DF403AE80F2DQ37855952-846C0D34-7404-41D8-AB78-7229E2368DACQ38011650-264B8F6A-A676-4F19-B0AC-32CE6FC187F6Q38217594-653C5144-7500-4DDC-A996-07FFC649E995Q38650013-148A623E-3796-4ACF-AA90-502FE340F945Q40176893-984B229D-FA99-4859-A9AC-3247E071BC5CQ40777946-D568C147-7E5F-4CD5-9373-E2058D615C1DQ40859133-EECA74C1-75CC-4837-A503-C5CC9895830CQ40895891-86C44639-8890-42F3-BDC1-E752CEC8A896Q42315772-EEBF9E13-D69E-4611-8176-2DC20D6E7E68Q42317148-61D35DEB-844B-403D-8E1E-38887692C731Q42783189-9717FA2F-500A-42AA-BBB4-1A550A225979Q52827001-5D1FF300-C88F-45E2-B845-2723DC3952AB
P2860
Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@ast
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@en
type
label
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@ast
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@en
prefLabel
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@ast
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@en
P2860
P356
P1476
Peptide-specific cytotoxic T l ...... gents for tumor immunotherapy.
@en
P2093
E Sadovnikova
H J Stauss
P2860
P304
13114-13118
P356
10.1073/PNAS.93.23.13114
P407
P577
1996-11-01T00:00:00Z